Automate Your Wheel Strategy on GILD
With Tiblio's Option Bot, you can configure your own wheel strategy including GILD - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowNews
Markets Haven't Changed. These 2 Cheap Dividends Still Rule
Published: April 01, 2026 by: Forbes
Sentiment: Neutral
Fear is up, markets are down—and we contrarians know that times like these are when we go shopping for cheap dividends.
Read More
Gilead Sciences, Inc. (GILD) M&A Call Transcript
Published: March 31, 2026 by: Seeking Alpha
Sentiment: Neutral
Gilead Sciences, Inc. (GILD) M&A Call Transcript
Read More
Here's Why Gilead Sciences (GILD) is a Strong Value Stock
Published: March 27, 2026 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Is Gilead (GILD) a Buy as Wall Street Analysts Look Optimistic?
Published: March 27, 2026 by: Zacks Investment Research
Sentiment: Neutral
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Read More
Can Gilead's Recent Acquisitions Strengthen Its Long-Term Growth Outlook?
Published: March 27, 2026 by: Zacks Investment Research
Sentiment: Positive
Gilead doubles down on acquisitions, adding immunology and CAR-T assets to diversify beyond HIV and strengthen its oncology pipeline.
Read More
Gilead Sciences to acquire Ouro Medicines, expanding autoimmune therapy portfolio
Published: March 24, 2026 by: Proactive Investors
Sentiment: Positive
Gilead Sciences Inc (NASDAQ:GILD, XETRA:GIS) announced it has entered into a definitive agreement to acquire Ouro Medicines, a privately held biotech company developing T cell engager therapies for autoimmune diseases. The acquisition adds OM336 (gamgertamig), a clinical-stage BCMAxCD3 bispecific T cell engager, to Gilead's inflammation portfolio.
Read More
Gilead nearing up to $2 billion buyout of biotech Ouro Medicines, FT reports
Published: March 23, 2026 by: Reuters
Sentiment: Positive
Gilead Sciences is nearing an acquisition of biotech firm Ouro Medicines for up to $2 billion, the Financial Times reported on Monday, citing people familiar with the matter.
Read More
Here is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending Stock
Published: March 19, 2026 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.
Read More
TrumpRx lists many medicines at prices higher than paid in UK
Published: March 18, 2026 by: Reuters
Sentiment: Negative
U.S. President Donald Trump pledged to make prescription drugs cheaper for Americans than anywhere in the world, but his TrumpRx.gov website is not delivering across the board lower prices than those paid in the United Kingdom, according to a Reuters comparison of publicly available prices.
Read More
Why Gilead Sciences (GILD) is a Top Value Stock for the Long-Term
Published: March 06, 2026 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Is Trending Stock Gilead Sciences, Inc. (GILD) a Buy Now?
Published: March 05, 2026 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Gilead Sciences, Inc. (GILD) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Published: March 03, 2026 by: Seeking Alpha
Sentiment: Neutral
Gilead Sciences, Inc. (GILD) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Read More
Why Gilead Sciences (GILD) is a Top Momentum Stock for the Long-Term
Published: March 02, 2026 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Gilead's experimental HIV treatment shows low discontinuation rates in studies
Published: February 25, 2026 by: Reuters
Sentiment: Positive
Gilead Sciences on Wednesday said its experimental single-tablet HIV treatment was generally well tolerated with low discontinuation rates, positioning the single-tablet regimen as a potential option for patients to switch to after the virus is already suppressed.
Read More
Gilead's Single-Tablet Regimen of Bictegravir and Lenacapavir Maintained Virological Suppression in People With HIV Who Switched Antiretroviral Therapy
Published: February 25, 2026 by: Business Wire
Sentiment: Neutral
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #CROI2026--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of new Phase 3 ARTISTRY-1 and ARTISTRY-2 trial data at CROI 2026 showing a treatment switch to an investigational, single-tablet combination regimen of bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN) was effective in people living with HIV with virological suppression, including those switching from complex multi-tablet regimens or a global guideline-recommended single-tablet regimen. The n.
Read More
GILD to Acquire ACLX for $7.8B & Gain Full Control of Anito-Cel
Published: February 24, 2026 by: Zacks Investment Research
Sentiment: Positive
Gilead is set to acquire Arcellx for $7.8B, gaining full control of anito-cel and boosting its cell therapy pipeline amid rising competition.
Read More
Gilead pays $7.8bn to take full control of promising multiple myeloma therapy
Published: February 23, 2026 by: Proactive Investors
Sentiment: Positive
Gilead Sciences Inc (NASDAQ:GILD, XETRA:GIS) has agreed to buy Arcellx in a deal valuing the clinical-stage biotechnology company at $7.8 billion, converting an existing partnership into outright ownership of a CAR T-cell therapy that could be approved by US regulators before the end of this year. The offer of $115 per share in cash represents a 68% premium to Arcellx's 30-day volume-weighted average share price as of 20 February.
Read More
Gilead shows its belief in its partner's cancer treatment with a $7.8 billion buyout
Published: February 23, 2026 by: Market Watch
Sentiment: Positive
Shares of Arcellx shot up toward a fresh record in early Monday trading, after Gilead Sciences agreed to buy the rest of the shares it doesn't already own of the biotechnology company, in a deal with an equity value of $7.8 billion.
Read More
Gilead Sciences to Buy Arcellx in Deal Valued at $7.8 Billion
Published: February 23, 2026 by: WSJ
Sentiment: Positive
Gilead Sciences has agreed to buy the rest of development partner Arcellx in a deal that values the biotechnology company at about $7.8 billion at closing.
Read More
Gilead to acquire Arcellx for $7.8 billion
Published: February 23, 2026 by: Reuters
Sentiment: Positive
Gilead Sciences said on Monday it will buy cancer therapy developer Arcellx for an implied equity value of $7.8 billion, sending shares of Arcellx climbing 77.8% to $113.99 in premarket trading.
Read More
Gilead Sciences to Acquire Arcellx to Maximize Long-Term Potential of Anito-cel
Published: February 23, 2026 by: Business Wire
Sentiment: Neutral
FOSTER CITY, Calif. & REDWOOD CITY, Calif.--(BUSINESS WIRE)-- #ACLX--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has entered into a definitive agreement to acquire Arcellx (Nasdaq: ACLX) for $115 per share in cash at closing and one contingent value right of $5 per share, which represents an implied equity value of $7.8 billion payable at closing. Arcellx is a biotechnology company focused on delivering a new class of innovative immunotherapies for patients with cancer and other incura.
Read More
Gilead Sciences to Acquire Arcellx to Maximize Long-term Potential of Anito-cel
Published: February 23, 2026 by: Business Wire
Sentiment: Neutral
FOSTER CITY, Calif. & REDWOOD CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has entered into a definitive agreement to acquire Arcellx (Nasdaq: ACLX) for $115 per share in cash at closing and one contingent value right of $5 per share, which represents an implied equity value of $7.8 billion payable at closing. Arcellx is a biotechnology company focused on delivering a new class of innovative immunotherapies for patients with cancer and other incura.
Read More
Time To Take Profits On Gilead Sciences (Rating Downgrade)
Published: February 20, 2026 by: Seeking Alpha
Sentiment: Negative
Gilead Sciences, Inc. shares have risen more than 43% over the past year. I continue to believe that its three key drugs remain Biktarvy, Yeztugo, and Livdelzi, whose total sales grew 10.8% year-over-year to $4.2 billion in Q4. On the other hand, sales of Gilead's oncology franchise leave much to be desired, despite its numerous attempts to compete with Merck, Pfizer, and AstraZeneca.
Read More
Is Most-Watched Stock Gilead Sciences, Inc. (GILD) Worth Betting on Now?
Published: February 19, 2026 by: Zacks Investment Research
Sentiment: Positive
Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
Gilead Sciences (GILD) is a Top-Ranked Momentum Stock: Should You Buy?
Published: February 13, 2026 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Can Gilead's HIV Portfolio Sustain Its Growth Trend in 2026?
Published: February 13, 2026 by: Zacks Investment Research
Sentiment: Positive
Gilead Sciences posts strong 2025 HIV growth despite a $900M headwind, as Biktarvy and Descovy lead and new launch Yeztugo gains momentum.
Read More
Focus on These 5 Stocks That Recently Hiked Dividends
Published: February 13, 2026 by: Zacks Investment Research
Sentiment: Positive
NTES joins four peers in lifting dividends as resilient markets, rate-cut hopes and volatility spur investors toward steady income plays.
Read More
GILD's Q4 Earnings Beat Estimates, HIV and Liver Disease Drugs Power Sales
Published: February 11, 2026 by: Zacks Investment Research
Sentiment: Positive
Gilead beats Q4 estimates on strong HIV and Liver Disease portfolio performance, but 2026 guidance tempers sentiment despite Yeztugo's solid debut.
Read More
Gilead Sciences Stock Surges to Record Highs Amid Bull Notes
Published: February 11, 2026 by: Schaeffers Research
Sentiment: Positive
Gilead Sciences Inc (NASDAQ:GILD) stock is up 5.7%, hitting a record high of $155.56 at last glance, after the biopharmaceutical company announced a top- and bottom-line win for the fourth quarter.
Read More
Will These 5 Drug Bigwigs Surpass Q4 Earnings Forecasts?
Published: February 09, 2026 by: Zacks Investment Research
Sentiment: Positive
Let's look at five pharma and biotech companies, AZN, INCY, GILD, VRTX and MRNA, which are scheduled to release their fourth-quarter 2025 results this week.
Read More
About Gilead Sciences, Inc. (GILD)
- IPO Date 1992-01-22
- Website https://www.gilead.com
- Industry Drug Manufacturers - General
- CEO Daniel O'Day
- Employees 17600